Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group.
about
Comparison of serum hepatitis C virus (HCV) RNA and core antigen levels in patients coinfected with human immunodeficiency virus and HCV and treated with interferon plus ribavirin.Multilaboratory Comparison of Hepatitis C Virus Viral Load AssaysClinical Evaluation of Two Methods for Genotyping Hepatitis C Virus Based on Analysis of the 5' Noncoding RegionComparative Evaluation of the Total Hepatitis C Virus Core Antigen, Branched-DNA, and Amplicor Monitor Assays in Determining Viremia for Patients with Chronic Hepatitis C during Interferon Plus Ribavirin Combination TherapyImprovement of Hepatitis C Virus (HCV) Genotype Determination with the New Version of the INNO-LiPA HCV AssayPerformance Characteristics of a Quantitative, Homogeneous TaqMan RT-PCR Test for HCV RNARapid and early virological response to chronic hepatitis C treatment with IFN 2b or PEG-IFN 2b plus ribavirin in HIV/HCV co-infected patientsSerum Alpha-Fetoprotein Predicts Treatment Outcome in Chronic Hepatitis C Patients Regardless of HCV GenotypeGenetic variation of hepatitis C virus in a cohort of injection heroin users in Wuhan, ChinaHCV genotyping using statistical classification approachRetreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data.Epidemiological changes in hepatitis C virus genotypes in France: evidence in intravenous drug users.Estimation of average diagnosis and treatment costs of hepatitis C.Using statistical models to assess medical cost of hepatitis C virus.Statistical count models for prognosis the risk factors of hepatitis C.Random effect model for identifying related factors to virological response in HCV patientsComparison of hepatitis C virus NS5b and 5' noncoding gene sequencing methods in a multicenter study.Clinical evaluation of the automated COBAS AMPLICOR HCV MONITOR test version 2.0 for quantifying serum hepatitis C virus RNA and comparison to the quantiplex HCV version 2.0 test.Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics.Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b during interferon or combined interferon-ribavirin therapy.Extent of liver inflammation in predicting response to interferon α & Ribavirin in chronic hepatitis C patients: a cohort study.Predicting the probable outcome of treatment in HCV patients.Peginterferon and ribavirin treatment for hepatitis C virus infectionInterferon for acute hepatitis C.Hepatitis C advances in antiviral therapy: what is accepted treatment now?Management of patients with hepatitis C in a community population: diagnosis, discussions, and decisions to treat.HCV chronic hepatitis in patients with HIV: clinical management issues.Review of the effect of highly active antiretroviral therapy on hepatitis C virus (HCV) RNA levels in human immunodeficiency virus and HCV coinfection.Monitoring of viral levels during therapy of hepatitis C.Role of liver biopsy in management of chronic hepatitis C: a systematic review.Review article: indicators and predictors of response to anti-viral therapy in chronic hepatitis C.Current therapies for chronic hepatitis C. Drug combination achieves sustained response in more than half of patients.Effect of pegylated interferon on non-responders and relapsers with interferon.Naturally occurring genotype 2b/1a hepatitis C virus in the United StatesHIV and HCV coinfection in haemophilia.Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation.Female Sex Hormones Pattern and Its Relation to Disease Severity and Treatment in Pre- and Postmenopausal Patients with Chronic Hepatitis C Virus (Genotype 4) InfectionImproved hepatitis C treatment response in younger patients: findings from the UK HCV National Register cohort studyMulticenter evaluation of the performance characteristics of the bayer VERSANT HCV RNA 3.0 assay (bDNA)Evaluation of the Abbott Real Time HCV genotype II assay for Hepatitis C virus genotyping.
P2860
Q27473034-EFAE6548-D460-4D7F-AD49-7DA81EB44A8DQ27473252-DCEB03F8-3F17-4B4B-82AA-0F4B768DDF0DQ27473463-45B132DB-AEE1-42D0-875D-9A74435C4600Q27477674-4971182A-F907-45F9-95B3-6572324E8E33Q27478358-961D4B4E-68BC-4CB2-9676-5CF7376FB5C9Q27480737-B499E3E1-80A7-4756-882A-4CF68BDC20F4Q27481046-8BCCF37E-2531-4E28-8F8B-A69CB42100CFQ27486169-4BE69C0D-EAFB-4D2C-BD0F-76A05B5901D0Q27486520-13CE833B-D232-452F-BA60-2328A7DAE39CQ27489079-52D4DF6D-7D89-4EC1-989D-FD7CE402A603Q30746310-753E2B2F-0370-47BD-A416-F51DB04B544BQ33183396-28C3B729-F653-4DCE-8BE7-72AFD05B0F5DQ33596466-3563ED27-A7FB-4BA6-AE9E-4D0563632BE2Q33596513-2A90D306-988A-4D1A-B7A1-4A6DE7408A19Q33596530-9FB155EA-332C-4E40-A833-986A0AADAC98Q33596718-8C21506E-3FA4-44F8-BF59-393147457CCBQ33825378-69952706-3780-41D5-A5FC-E73D7F84DC26Q33968828-36174281-6E30-4790-993D-FFE5C16C6ADAQ33970328-EE17FB92-B206-4A2B-BCEA-EB0B28C0D7F7Q34099523-3ECDA4E9-38BB-4679-A035-0AC6E2547B9CQ34304221-FC284ECA-AF51-47DB-9EAC-B929E235A6DBQ34409039-02CDA82E-E9B1-4E82-9501-2AF674EE9095Q34521371-E91A2CA8-98E9-41C4-9D6A-772F4C88AD6FQ34546599-1722C979-AE5E-42BF-9DD7-81F5A4F93997Q34619384-1BD3C0A4-3E59-4667-ACB9-DDC9CD16624EQ34628400-9C95C5D9-AE2A-488B-AE50-70CB1FD027B0Q34756205-F7A58AC6-26DA-409B-BC41-C5FBC454ED06Q34849390-D08B8C36-3722-4FE4-AAC5-8454AB97A1E9Q34984089-D81FF629-DF6B-4B36-B128-E1A6094EFA6AQ34984098-85C5A8C6-0216-4EFF-A2F2-E68F7D1EF41DQ35086844-B6A1D7AA-094F-49CE-9A22-5752E2465A2CQ35182682-D500D5A8-3FC2-4A43-BBBF-EEB994760960Q35217294-FB438EAC-8CB8-4C34-93B2-32BDEDB6D8D4Q35487437-72DEBF56-83D0-4AEC-8C2F-DEE1B508D0C6Q35666754-E6D51797-E63C-461A-9516-5A8CF479265BQ36057034-08C2E5AE-F8A9-4EA5-90DC-2A605D9BDDC4Q36112618-03383E3C-FBF3-41DA-B73C-3FFEB3E6B713Q36238748-4B336894-7FE9-42B6-888A-64A2836580A1Q36240147-1E446FE7-2B62-499A-9EAD-7F7B5A26DE79Q36270128-ADBC9EF0-7883-4EA7-BE36-B365679181F8
P2860
Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Is an "a la carte" combination ...... C? The ALGOVIRC Project Group.
@en
Is an "a la carte" combination ...... C? The ALGOVIRC Project Group.
@nl
type
label
Is an "a la carte" combination ...... C? The ALGOVIRC Project Group.
@en
Is an "a la carte" combination ...... C? The ALGOVIRC Project Group.
@nl
prefLabel
Is an "a la carte" combination ...... C? The ALGOVIRC Project Group.
@en
Is an "a la carte" combination ...... C? The ALGOVIRC Project Group.
@nl
P2093
P356
P1433
P1476
Is an "a la carte" combination ...... C? The ALGOVIRC Project Group.
@en
P2093
J Albrecht
J McHutchison
P304
P356
10.1002/HEP.510310131
P407
P577
2000-01-01T00:00:00Z